Phase II data on Roche's etrolizumab published in The Lancet shows...

Phase II data on Roche's etrolizumab published in The Lancet shows high clinical remission rates in moderate-to-severe ulcerative colitis Roche has announced that phase II clinical data published in The Lancet shows clinical remission in 43.8 percent of patients with moderate-to-severe ulcerative colitis , a type of inflammatory bowel disease.


More...